Anges Inc. (4563) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Anges Inc. (4563:JPX), powered by AI.

Current Price
¥61
P/E Ratio
-0.5
Market Cap
14.4B
Sector
Healthcare
What is the Anges Inc. stock price forecast?

Anges Inc. is currently trading at ¥61. View real-time AI analysis on Alpha Lenz.

What is Anges Inc. insider trading activity?

View the latest insider trading data for Anges Inc. on Alpha Lenz.

What is Anges Inc.'s P/E ratio?

Anges Inc.'s P/E ratio is -0.5.

Anges Inc.

¥61.00
JPX4563
Ask about Anges Inc.'s future dividend policy...
Alpha Chat Insight

Anges Inc. trades at a P/E of -0.5 (undervalued) with modest ROE of -199.1%. 3Y revenue CAGR of 115.7% highlights clear growth momentum.

Ask for details

Company Overview

Anges Inc. is a biotechnology company focused on the research, development, and commercialization of gene-based therapeutics and vaccines. Established in Japan, it primarily aims to innovate within the life sciences sector by developing treatments for critical and rare conditions that currently lack effective medical solutions. A standout feature of Anges Inc. is its emphasis on gene therapy and DNA vaccines, a progressive approach in combating various diseases that impact both global and community health. The company channels its expertise into creating groundbreaking solutions, predominantly impacting the healthcare and pharmaceuticals industries by addressing unmet medical needs. Through collaborations and partnerships with academic institutions and other biotech firms, Anges Inc. plays a pivotal role in advancing medical research and therapeutic possibilities. Such endeavors not only contribute to medical innovation but also position the company as a key player in the biopharmaceutical market, especially in areas where traditional therapeutic methods have fallen short.

CEODr. Ei Yamada M.D., Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees55

Company Statistics

(FY 2024)

Profile

Market Cap¥14.36B
Revenue¥643.64M
Shares Out0.00
Employees55

Margins

Gross38.48%
EBITDA2232.52%
Operating-1415.31%
Pre-Tax-4294.91%
Net-4370.31%

Valuation

P/E-0.51
P/B6.66
EV/Sales22.30
EV/EBITDA0.90
P/FCF-2.15

Growth (CAGR)

Rev 3Yr115.69%
Rev 5Yr14.52%
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-167.63%
ROE-199.07%
ROIC-54.29%

Financial Health

Cash & Cash Equivalents¥1.71B
Net Debt¥804.25M
Debt/Equity116.48%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Anges Inc. (Healthcare) Stock Forecast & Analysis ¥61 | Alpha Lenz